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Abstract
Objectives: The present pilot study aims to investigate
DNAmethylation changes of genes related to fibromyalgia
(FM) development and its main comorbid symptoms,
including sleep impairment, inflammation, depression
and other psychiatric disorders. Epigenetic modifications
might trigger or perpetuate complex interplay between
pain transduction/transmission, central pain processing
and experienced stressors in vulnerable individuals.
Methods: We conducted DNA methylation analysis by
targeted bisulfite NGS sequencing testing differential
methylation in 112 genomic regions from leukocytes of
eight women with FM and their eight healthy sisters as
controls.
Results: Tests for differentially methylated regions and
cytosines brought focus on the GRM2 gene, encoding the
metabotropic glutamate receptor2. The slightly increased
DNA methylation observed in the GRM2 region of FM pa-
tients may confirm the involvement of the glutamate
pathway in this pathological condition. Logistic regression
highlighted the simultaneous association of methylation
levels of depression and inflammation-related genes
with FM.
Conclusions: Altogether, the results evidence the gluta-
mate pathway involvement in FM and support the idea that
a combination of methylated and unmethylated genes
could represent a risk factor to FMor its consequence,more
than single genes. Further studies on the identified bio-
markers could contribute to unravel the causative under-
lying FM mechanisms, giving reliable directions to
research, improving the diagnosis and effective therapies.
Keywords: biomarkers; DNA methylation; epigenetics;
fibromyalgia.
Introduction
Fibromyalgia (FM) is a pathological condition characterized
by abnormal pain processing leading to chronic widespread
pain (CWP) [1–4]. Because of the extensive array of symp-
toms associated with the condition, including disrupted
sleep, depression, mental health disorders and low grade
inflammation, a long debate on its definition and classifi-
cation criteria [5–8] has made its diagnosis complex [9].
Recently, theworldwideprevalence of FMhas been reported
to range from 1 to 5% of the general population [10], being
more common in females [11, 12]. Since the disease leads to a
poor quality of life and high medical costs often without
positive outcome of the selected treatment, FM represents a
major social and health problem.
The etiopathogenesis of thismultifactorial condition and
the role of comorbidities, if causes or symptoms of the dis-
ease, are still a matter of debate. One of the hypothesized
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mechanisms in the FM pathophysiology is central sensitiza-
tion [13], in which nociceptors, neurons and glia processing
pain signals seem to undergo alterations and become sensi-
tized in vulnerable individuals [14]. Thus, it is proposed that
vulnerability to pain in patients with FM may reflect differ-
ences in central mechanisms that have been shown deter-
mined by both genetic and environmental factors.
The genetic influence was supported by a high preva-
lence of FM and reduced pressure pain thresholds among the
offspring of FM mothers [15, 16]. Single-nucleotide poly-
morphisms affectingfiber connectivity and cognition [17] and
related to the serotonergic [18], dopaminergic, catechol-
aminergic [19–21] and the endogenous opioid system [22–24]
have been investigated using candidate gene approaches.
However many of these studies failed to provide association
with FM or related symptoms [25]. Then genome wide scans
with no a priori assumptions tried to override confounding
factors arising from FM comorbidities, highlighting a prob-
able inflammatory basis of the syndrome [26] and a potential
role of central nervous system (CNS) dysfunction [27].
Environmental influences have also been shown to play
a great role in FM, especially daily life personal stressful
experience, childhood maltreatment, such as neglect,
emotional abuse and traumatic experiences. A complex
interaction of genetic factors with dysfunctions in the HPA
(hypothalamic-pituitary-adrenal) axis has been hypothe-
sized to determine an individual’s predisposition to somatic
or psychological pathologic response to trauma [28].
To date, the above identified genetic and environmental
factors have not fully explained the etiology of FM [29]. The
molecular mechanisms responsible for the increased pain
sensitivity in response to external stimuli could be DNA
sequence–independent mechanisms regulating gene
expression [30]. Evidence is emerging for a central regula-
tory role of epigenetics in influencing the neurobiological
mechanisms of chronic pain generation [31].
Among the epigenetic changes, DNA methylation, the
addition of a methyl group on the fifth positions of the
cytosine in the DNA, catalyzed byDNAmethyltransferases,
stably alters gene expression in response to transient
stimuli [32], potentially reflecting and revealing environ-
mental predispositions to FM. This epigenetic change
occurs mainly in the context of CG dinucleotides, which
tend to cluster in regions called CpG islands with a GC
content of at least 50%. Approximately 60% of gene pro-
moters are associated with CpG islands [33].
A few studies have investigated the methylome in blood
cells of FM subjects [34]. Menzies and coworkers (2017) found
differentially methylated sites located in genes belonging to
biological clusters significantly related to neuron differenti-
ation, development and chromatin compaction [35]. In
addition, a hypomethylated DNA pattern in FM patients
compared to controlswas found enriched in genes implicated
in stress response and DNA repair/free radical clearance [36].
Another study investigated the DNA methylation status in
CWPconditions, identifyingdifferentiallymethylatedCpGs in
malate dehydrogenase 2 (MDH2; p-Value 0.017), tetranectin
(CLEC3B; p-Value 0.039), and heat shock protein beta-6
(HSPB6; p-Value0.016) [37].Anepigenome-widemethylation
scan through MeDIPseq in whole blood DNA from 1708
monozygotic and dizygotic Caucasian twins highlighted
neurological pathways’ involvement in CWP, with associa-
tion signals mapping in or near to IL17A, ADIPOR2, and
TNFRSF13B [38].
Based on this promising evidence and the technology
advances in epigenetic analyses, the present pilot study
aimed to investigate changes in DNAmethylation potentially
affecting the genes related to FM development and its main
symptoms by comparing FM women with their healthy sis-
ters. To this purpose, we measured the presence of this
epigenetic mark through a target enrichment-designed li-
brary specifically including promoters and CpG regions of
genes previously found associatedwith FM, CWP, depression
and other psychiatric disorders, sleep problems and inflam-
mation. The current pilot studywill guide further analyses for
replicating preliminary results in a larger sample.
Methods
Subjects
Asubset of 16participants (8FMwomenpatients andeight relatedhealthy
sisters) were selected for the present study from a large sample of 543
families in which at least one member was diagnosed with FM. The FM
patients were recruited according to the following criteria: subjects with
FM diagnosis assessed by a professional specialist in rheumatology
(Hospital of Pontevedra, Spain) and by the Unit of Pain of the CHUS
(Complejo Hospitalario Universitario de Santiago, Spain) using the ACR
(American College of Rheumatology) 2010 criteria. All the participants
were classified into the diagnostic groups described in Table S1. The eight
FMwomenwere randomly selected among those belonging to diagnostic
group 5 (FM patients, with and without comorbid symptoms/disorders
related to the syndrome, but no other pathologies) andhaving at least one
healthy sister with no pain (group 1). All the experiments were performed
in accordance with the relevant guidelines and regulations and the study
design was approved by the Ethics Committee of Galicia, Spain (Regis-
tration Code: 2013/582; Amendment: November 2017), and written
informed consent was obtained from all participants. All the subjects
accepted to enter the study as volunteers.
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Demographic and clinical assessment
The eight (8) unrelated Caucasian FM patients were females, aged 39–
63 years (mean age 51 ± 7.87 years). For each FM patient, a healthy
sister, a total of eight (8) subjects (females, aged 33–71years,mean age
52.6 ± 12.3 years), was selected as control.
All the participants, subjects and controls, were submitted to a
clinical interview about demographic data and the following tests
were administered (Table S2): Fibromyalgia Impact Questionnaire
(FIQ) [39, 40]; Visual Analog Scales (VAS) to assess the core symptoms
of FM [41]; Pittsburgh Sleep Quality Inventory (PSQI) [42, 43]; Beck
Depression Inventory (BDI) [44, 45].
Exclusion criteria
Exclusion criteria were the presence of other chronic pain diseases or
other disorders that may explain the main symptoms of FM. For
healthy controls, the requirement was no acute or chronic pain
problems, or mental disorders.
Sample collection
Peripheral whole blood collection, two tubes of 10mL per subject, was
performed via venipuncture and leukocytes were separated through a
washing protocol. The blood was mixed well and centrifuged at
2800 rpm for 10 min, 4° C. The white cell phase was collected and
mixed with Cell Lysis Buffer. After 10 min at room temperature, the
samples were centrifuged at 1800 rpm for 10 min, 4 °C. Distilled water
was mixed to the obtained leukocytes’ pellet and centrifuged at
1800 rpm for 10 min, 4 °C. Saline solution (0.9%) was finally added to
the leukocytes’ pellet. A DNA purification protocol for leukocytes was
performed using QIAamp DNA Blood Midi/Maxi Kit (Spin Protocol,
QIAGEN) at the Galician Public Foundation of Genomic Medicine of
the University of Santiago de Compostela (Spain). Aliquots of the
genomic DNA extractedwere sent to Aalborg University, Denmark, for
the present epigenetic study.
DNA methylation analysis
A targeted DNA methylation analysis was conducted through a
customized SureSelectXT Target Enrichment System for Illumina
Paired-EndMultiplexed Sequencing Library (SureSelectXT cat # 5190-
4806 and #G651A, Agilent Technologies, Santa Clara, CA), a single-
base resolution approach, based on bisulfite conversion [46]. The
protocol included five main steps. i) Capture library preparation: a
pool of synthetic RNA fragments complementary to the selected
genome regions, 4818 probes in total, were synthesized for a genome
coverage of 240.134 kbp using the Agilent SureDesign tool. The
selected regions of interest were related to CpGs islands, promoters
and transcription start sites of 100 genes (Table S3), identified using
the UCSC genome browser (on Human Dec. 2009 (GRCh37/hg19)
Assembly; https://genome-euro.ucsc.edu/cgi-bin/hgGateway). The
‘Nucleotide’ molecular database (National Library of Medicine, US)
and the Ensembl genome browser (www.ensembl.org, n.d.) were
used to determine the exact DNA sequences to be included in the
library and to explore genes information. ii) gDNA shearing: samples
quantified using Qubit and DNA (3 µg for each subject) were
sonicated with Covaris® S2 system (Covaris, Woburn, MA) to obtain
products of 150–250 bp. iii) Hybridization and capture: DNA was first
end-repaired, A-tailed and ligated with paired-end methylated
adapters to create a pre-capture DNA library, using SureSelectXT
Library Prep Kit ILM; sample purifications were conducted using
AMPure XP beads andmagnetic separator devices. The DNA samples
(500 ng) were then hybridized to the RNA SureSelect Humanmethyl-
seq capture library at 65 °C for 16 h and hybridized products were
captured using streptavidin-coated beads. iv) Bisulfite conversion of
the purified hybridized products (64 °C for 2.5 h) using the Zymo EZ
DNA Gold kit (Cat #D5005, Zymo Research, Irvine, CA) and the
bisulfite-treated library was PCR-amplified for 14 cycles. v)
Sequencing: the captured libraries were finally amplified with 8 bp
indexing primers appropriate for each sample (six cycles PCR); the
indexed samples (4 ng/μL) were clustered at 12 pM denatured li-
braries on a V3 paired-end read flow cell (MiSeq Reagent Kits v3) and
sequenced for 600 cycles on an Illumina MiSeq platform.
Bioinformatic data processing: bisulfite-treated 200 nt-long
paired-end sequencing reads were aligned to the human reference
genome (GRCh37/hg19) using BS-Seeker2 [47] with standard parame-
ters. Each mate of the pair was mapped in single-end mode and the
resulting alignments merged, as recommended. Conversion of the
alignment files to the CGmap format has been performed using
CGmapTools [48] with the -rmOverlap option to remove overlapping
regions of two mate reads avoiding dual consideration of the same
DNA fragment. Finally, Metilene [49] was used for the identification of
differentially methylated regions and cytosines.
Differential methylation was performed for all the cytosine en-
vironments; analysis of methylated cytosines in GCH and CHH con-
texts was also considered.
Statistical analyses
Metilene software, with a binary segmentation algorithm combined
with a two-dimensional statistical test [49], was used for the detec-
tion of differentially methylated regions (DMRs, test parameters: -M
500 -f 2 -m 5 -d 0.01) and differentially methylated cytosines (DMCs,
test parameters: -f 3-m 5 -d 0.1). In particular, the software assesses
the statistical significance of potential DMRs by a two-dimensional
version of the Kolmogorov–Smirnov test (KS-test) [50] and an inde-
pendent Mann–Whitney U test (MWU-test). The software Metilene
assesses each CpG for differential methylation (DMCs test) by using
the Mann–Whitney-U test. The corresponding p-Values are reported
in the output.
A logistic regression model was used to test the concurrent effect
of different methylation levels on the risk of developing FM. Logistic
regression is the most appropriate model to estimate the risk of a
disease, given the possibility to use a dichotomous variable as a
dependent variable. In this case, 0 corresponded to FM absence, one
corresponded to FM presence. The set of explanatory variables (age,
which was included to control for potential confounding effects, level
of methylation in FM, depression, sleep and inflammation regions,
respectively) checked for the influence of methylation levels on the
risk of FM in some selected groups of genome regions already known
as associated with either FM, depression, sleep, or inflammation.
Robust standard errors were applied to the regressionmodels in order
to reduce the possible bias introduced in the estimations by hetero-
scedasticity. The logistic analysis was conducted in Stata/IC 15.1
(StataCorp, TX 77845, USA).
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It should be noted that the methylation values have been multi-
plied by 1000 in the model. This operation was necessary to better
highlight the effects of the methylation levels on the risk of FM.
For all the statistical analyses, results were considered statisti-
cally significant for p≤0.05.
Results
DNA methylation analysis comparing cases
and controls
We performed DNA methylation analysis testing for dif-
ferential methylation in targeted genomic regions in leu-
kocytes from women with FM (n= 8). Their related healthy
sisters (n= 8) with similar age have been selected as con-
trols. Siblings offer in fact a good study design to investi-
gate the association of DNA methylation with a disease,
sharing half their genome and often stable aspects of
family context, allowing to reduce confounding influences
due to genetic heterogeneity and potentially different
prenatal exposures or early-life environmental effects.
The targeted sequences to be analyzed were related to
potentially relevant genes for FMdevelopment or comorbid
symptoms and were identified through a literature review.
A total of 112 genomic regions belonging to 100 genes were
selected, based on previous associations with FM or CWP,
depression and other psychiatric disorders, inflammation,
peripheral fiber innervation and sleep disorders. Regions
related to chromatin regulation and miRNAs genes were
also included (Tables S3, S4).
The DNA methylation analysis was performed at two
levels: a differentially methylated regions (DMRs) test
determining methylation by grouping neighboring cyto-
sines and a differentially methylated cytosines (DMCs) test
revealing methylation at single cytosine level.
DMRs test revealed two regions (GRM2 and DRD3)
with a small but significant difference in the level of DNA
methylation. The results and the chromosomes’ co-
ordinates related to the two identified DMRs are listed in
Table 1. The first region (chr3: 51740486–51741687) is
related to the GRM2 gene promoter and includes a CpGs
island; the level of methylation resulted significantly
higher (p (MWU)=1.80E-06) in FM patients (mean
methylation: 0.1) than controls (mean methylation:
0.087). The GRM2 gene encodes the Glutamate Metabo-
tropic Receptor 2 (mGlu2) [51], that regulates the gluta-
matergic neurotransmission and can be perturbed in
many neuropathologic conditions [52]. However, after
correction for multiple comparisons the difference in
methylation level remained significant using only the
MWU statistical test (adjusted pval <0.0002). The second
region (chr3: 113897675–113898814) is related to the DRD3
gene promoter region encoding the dopamine receptor D3.
Even in this case the level of methylation was significantly
higher (p(MWU)=0.028) in the eight FM women (mean
methylation: 0.030) compared with their healthy sisters
(mean methylation: 0.006). However, the significance
was not revealed by the KS-test and disappeared after
correction for multiple comparisons with the MWU test.
Bisulfite conversion associated to NGS sequencing
allowed to reveal the methylation level also at single-base
resolution. Since DNA methylation can also occur in non-
CpG methylation contexts in human genome, we extracted
methylation levels even in CHH and CHG contexts (H=A, C
or T). The analysis revealed that in CHG and CHH contexts
only 1.377 and 1.289% of cytosines were methylated
respectively, indicating that the methylation trend did not
seem to be affected or biased bymethylation levels in these
contexts.
DMCs test revealed instead 23 differentiallymethylated
cytosines (methylation difference≥10%), belonging to 10
genes, that reached statistical significance (p<0.05) (Ta-
ble 2). Increased methylation in FMwomen compared with
their healthy sisters was found in cytosines related to SYT2,
Synaptotagmin 2; GCSAML, Germinal Center Associated
Signaling and Motility Like; GRM2, Glutamate Metabo-
tropic Receptor 2; MAOB, the Monoamine Oxidase B; and
the oncogene MCF2. Decreased methylation in FM women
compared with their healthy sisters was evidenced in cy-
tosines related to NR3C1, Glucocorticoid Receptor; TRPA1,
the Transient Receptor Potential Cation Channel Subfamily
A Member 1; ZNF438, Zinc Finger Protein 438; IL25, Inter-
leukin 25; and SAMD4A, Sterile Alpha Motif Domain Con-
taining 4A. Ten of the 23 CpGs differentially methylated
Table : Metilene DMRs test output: regions in which a significant difference of at least % in methylation levels was found using either the
MWU or the D KS test.
Gene Chr Start Stop #CpGs p (MWU) p (D KS) Mean methylation level CTRLs Mean methylation level FM
GRM chr    .E- . . .
DRD chr    .  . .
CTRLs, control subjects; FM, fibromyalgia patients.
4 Gerra et al.: DNA methylation changes in fibromyalgia
were related to GRM2 gene. Once again this indicates that
this region is an important target among the sequences
analyzed. Three DMCs were evidenced in the GCSAML
(germinal center associated signaling and motility like)
gene on chromosome 1, encoding a putative signaling
protein associated with the sites of proliferation and dif-
ferentiation of mature B lymphocytes [53]; two DMCs were
from the SAMDA4 gene andMCF2 gene. The other six genes
presented a single differential methylated CpG. However,
when applying the correction for multiple comparisons no
differences persisted in the DMCs test.
The effects of DNA methylation on FM risk
With FM being a multifactorial condition, the co-occurrence
of DNA methylation variation in different genome regions
may increase the risk of developing this condition more than
changes in a single region. For this purpose, a logistic
regression model evaluated the methylation levels in the
genes grouped based on their association with FM, depres-
sion, sleep, inflammation, chronic pain, psychiatric disor-
ders, innervation, chromatin regulation and miRNAs in
relation to the risk of developing FM (Table 3A, B). A first
model (not shown here) brought us to reduce the number of
regions investigated after application of the Variance
Inflationary Factor, which allowed highlighting the contri-
bution of the single variables on the overall multicollinearity.
The strong correlation among some of the variables led to the
exclusion of the methylation levels in the regions related to
chronic pain, psychiatric traits, innervation, chromatin
regulation and miRNAs. The results (Table 3B) revealed that
the level of methylation in the regions related to depression
and inflammation were significantly associated with FM: a
unit increase in the methylation level of depression-related
genes corresponded to a significantly 32.57 times higher risk
of suffering from FM (OR 32.57; <0.0001) compared with the
related healthy sisters. On the other hand, a one-unit increase
in the level of methylation in inflammation-related genes
significantly reduced the risk of FM by 57% (OR 0.428;
p=0.001).
Discussion
The present study selected a large number of candidate
genes, including not only genes previously associated with
FM but also with FM symptoms. Comparing FM with con-
trol samples, we observed differences in the methylation
levels of the GRM2 gene, which plays an important role in
encoding the type-2 metabotropic glutamate receptors
Table: DMCs test output: cytosines inwhich a significant difference inmethylation levels of at least%hasbeen foundusing theMWU test.
Gene Chr Start Stop p-Value (MWU) Mean methylation CTRLs Mean methylation FM
SYT chr   . . .
GCSMAL chr   . . .
chr   . . .
chr   . . .
GRM chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
chr   . . .
NRC chr   . . .
TRPA chr   . . .
ZNF chr   . . .
IL chr   . . .
SAMDA chr   . . .
chr   . . .
MAOB chrX   . . .
MCF chrX   . . .
chrX   . . .
CTRLs, control subjects; FM, fibromyalgia patients.
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(mGluR2) and a simultaneous significant association of
levels of methylation of depression and inflammation-
related genes with FM.
DNA from simple blood extraction might be used to
develop noninvasive molecular tests. In fact, some evidence
shows a blood-brain methylation correspondence [54] with
specific overlapping signatures of chronic pain in DNA
methylation of prefrontal cortex and peripheral T cells [55].
Targeted bisulfite sequencing analysis has been confirmed as
a valid approach to overcomepotential biases and to increase
the accuracy ofmethylation quantitativemeasures and ledus
to detect both regions (DMRs) and single cytosines (DMCs)
that might represent potential biomarkers for FM.
Both DMCs and DMRs tests bring the focus on the
GRM2 gene. In particular, an increasedmethylation level in
the GRM2 promoter region was observed in FM women
compared with their healthy sisters. GRM2 encodes the
type-2 metabotropic glutamate receptors (mGluR2), an
inhibitory auto-receptor that modulates glutamatergic
signaling throughout the central and peripheral nervous
system [56, 57] and indirectly modulates other neuro-
transmitters including dopamine and GABA [58]. The
activation of mGlu2 and mGlu3 receptors in peripheral
sensory neurons was demonstrated to be sufficient for
analgesia [59, 60], and consistently, pharmacological in-
hibition can prolong pain-like behavior [61, 62]. The ability
of mGluR2s to reverse the sensitization of capsaicin re-
ceptors and the thermal hyperalgesia induced by prosta-
glandin E2 suggested this receptor as a therapeutic
intervention in inflammatory pain states [63, 64].
Based on this evidence, we could hypothesize
(Figure 1) that the increased DNA methylation observed in
FM women may in some way reflect a lower mGlu2 mRNA
expression, a lower availability ofmGlu2 receptors, a lower
inhibition on glutamate release and an increased level of
glutamate, triggering the central sensitization state found
in FM patients [65–69]. Further, the potential role of GRM2
in the FM pathogenesis is supported by its involvement in
the sleep regulation pathway, proved in Grm2/3 double
knockout (Grm2/3-/-) mice [70].
The DMRs test revealed another hypermethylated re-
gion in FM women compared with controls related to the
DRD3 gene. DRD3, encoding dopamine receptor D3, has
been hypothesized to be involved in the pathophysiology
of several psychiatric disorders, including schizophrenia
[71]. Among the dopamine receptors, D3 receptors have the
highest density in the limbic areas of the brain, which are
associated with cognitive and emotional functions [72].
Disrupted dopaminergic neurotransmission is one of the
hypothesized triggering mechanisms in FM development,
with lower concentrations of dopamine found in FM pa-
tients in comparison with matched controls [73]. In addi-
tion, a positron emission tomography experiment showed
that abnormal dopamine function may be associated
with differential processing of pain perception [74]. Inter-
estingly, studies have demonstrated direct interactions of
D3 receptors at glutamatergic synapses and modulation of
glutamate activity by D3 receptor blockade [71].
The DMCs analysis in FMwomen and controls revealed
differently methylated cytosines also in other genes. In
Figure 1: Hypothesis on GRM2 hypermethylation consequences in FM patients. Glutamatergic neurotransmission key players are reported
(Glu: Glutamate; mGluR: Metabotropic glutamate receptor; vGluT: Vesicular glutamate transporter; EAAT: Excitatory amino acid transporter;
NMDA (N-methyl-D-aspartate), AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate), and kainate (kainic acid) receptors).
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particular, three cytosines were found differentially
methylated in the GCSAML gene. Consistently with our
results, the GCSAML expression was found downregulated
in a genome-wide expression profiling in the peripheral
blood of patients with FM [75]. Interestingly, a recent study
discovered the occurrence of maternally inherited 5mCpG
imprints at the DMR linked to this protein-coding gene and
demonstrated its potential influence on transcription fac-
tors expression from the paternal allele [76].
Moreover, increased methylation was observed in
other cytosines related to SYT2, already associated with
long-term changes in DNA methylation in a chronic pain
model [77]; MAOB, a potential biological candidate for
pain because of the significant associations between the
A/G polymorphism and postoperative perception of pain
[78]; MCF2, the SNP rs12556003 of which was associated
with FM [79]. The genes with decreased methylation in
FM women in the cytosines identified are NR3C1, for
which a hypomethylation was found to be associated
with post-traumatic stress disorder [80]; TRPA1, for
which a hypermethylation in subjects with a low pres-
sure pain threshold was demonstrated [81]; IL25, for
which an upregulated expression of the inflammatory
cytokines (IL10, IL25 and 1L36A) was already evidenced
in FM [75].
An interesting result highlighted by the logistic
regression analysis revealed the simultaneous association
of methylation levels of depression and inflammation
genes with FM. This strong association may support the
hypothesis that a methylome pattern, a combination of
several methylated/unmethylated genes, might represent
a risk factor to FM or a consequence of the disease, more
than single genes. The DNA methylation pattern in the
regions related to depression and inflammation genes may
reflect or cause the complex phenotype of FM susceptibility
(Figure 2). An increased level of methylation in the
analyzed sites of depression-related genes should be re-
flected in a lower expression of these genes that are
involved in excitatory neurotransmission as in the seroto-
ninergic pathway, mechanosensory behavior, post syn-
apse, neuron spine and dendrite functions [82]. A
decreased level of methylation in inflammation-related
genes should be associated with a higher level of their
expression, consistently with the upregulation of several
inflammatory pathways previously evidenced in FM pa-
tients [75]. Ahigher level of inflammation andahigher level
of depression in FM patients may lead to highlight the
complex interplay between physical and psychological
exhaustion in which subjects suffering from FM are held.
Concerning the role of depression and inflammation
genes, our results recall the bidirectional communication
between the brain and the immune system [83]. Immune
cells, including lymphocytes, express neurotransmitter
receptors that allow the interaction with circulating
Figure 2: Hypothesis on the effect of DNA methylation changes in depression and inflammation genes. DNA methylation changes in genes
previously associated to depression and inflammationwere found significantly associatedwith FM in the logistic regressionmodel comparing
eight FM women and their eight healthy sisters.
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neurotransmitters and neurochemicals. Thus, signals from
the brain can influence the immune system in response to a
changing external environment, including psychological
and physiological stress [84]. In turn, immune cells pro-
duce signaling molecules including catecholamines and
cytokines acting in the neuro-immunomodulatory circuitry
[85–87]. The fact that FMmay be a disorder associated with
immune dysregulation is also supported by the IgG defi-
ciency observed in FM patients [88, 89]. In addition, low-
dose naltrexone, observed tomodulate the immune system
function of the body to resist an abnormal immune
response [90], has been demonstrated to reduce symptom
severity also in FM, supporting the notion of immune
modulation and glia cell modulation in FM patients [91].
Inflammatory cytokines may reflect the brain and immune
system interaction resembling the core symptoms of FM
and other Central Sensitivity Syndromes [89]. These in-
teractions affect also the circadian rhythms potentially
explaining the sleep disorders associated with FM [92].
Although the individual differences in methylation
levels are rather small, the identified signatures in the
blood cells should be taken into account to verify themon a
larger subset of subjects and for future epigenetically
based biomarker development.
The present study has certain limitations. First, the
low number of samples highlights the need to confirm the
results by increasing the number of patients and controls.
A second limitation of the study is that psychosocial
factors have been observed to represent more than a
simple association with FM but appear as factors that
mainly contribute to the risk condition. The lack of in-
formation concerning early life events or stressor experi-
ences does not permit us to evaluate the association of
traumatic stress on FMdevelopment. Moreover, given that
sex-related differences in DNA methylation levels have
been previously reported [93, 94], we performed the pre-
sent pilot study only including a sample of women. We
acknowledge this may be a limitation, concerning the
generalization of results to male patients with FM.
Another limitation is the low startingmaterial that did not
allow a transcriptional analysis. Therefore, the relation-
ship between DNA methylation and mRNA levels should
be examined in future replication studies. In addition,
most of the changes in DNA methylation patterns were
observed in peripheral cells that may not reflect changes
in central pain mechanisms. Replication studies using
specific brain and dorsal root ganglia tissues should help
to further clarify the role of DNA methylation in FM.
Finally, it is not possible to establish any causal rela-
tionship on the differences highlighted. Future longitu-
dinal designs including both environmental and
methylation data might clarify the specific causal re-
lations between the factors involved, revealing if they are
linked to the etiology of the disease.
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